NCT06979076View on ClinicalTrials.gov

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2026

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions
CLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Interventions
DRUG

MS-553, DS1

Oral, Dose Schedule 1

DRUG

MS-553, DS2

Oral, Dose Schedule 2

Sponsors
All Listed Sponsors
lead

MingSight Pharmaceuticals, Inc

INDUSTRY

NCT06979076 - A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | Biotech Hunter | Biotech Hunter